Forum Agenda

July 24,09:00-11:40

Novel Anti-Tumor and Autoimmune Therapeutics Session

Stay tuned

09:00-09:20 Personalized Cancer Immunotherapy: Current Status and Future
Bin Li: Researcher, Shanghai Institute of Immunology

 

09:20-09:35 Strategic Roadmap for Emerging Biopharma Companies Entering the Japanese Market
Motoki FUJII: Senior Official, Regulatory Affairs Division, EPS

 

09:35-09:50 R&D Landscape, Emerging Trends, and Opportunities in Autoimmune Diseases
Shuona Yuan: Senior Research Analyst, PharmCube

 

09:50-10:05 Practical Strategies and Case Studies in Global Clinical Development of Novel Oncology Drugs
Shengjun Zhang: General Manager, BioTrialMed

 

10:05-10:20 From Design to Detection: Precision Screening with End-to-End Guidance
Lei Huang: Head of Translational Medicine, Burning Rock Biotech

 

10:20-10:40 Break

 

10:40-10:55 Reshaping Translational R&D Decision-Making for Advanced Therapies and Novel Drug Modalities with QSP Models
Chen Zhao: Professor and Ph.D. Supervisor, Nanjing Medical University; Distinguished Medical Expert of Jiangsu Province

 

10:55-11:10 Innovative Therapies Session: Next-Generation Fully Humanized Mouse Models Empowering Breakthroughs in Oncology and Autoimmune R&D
Wenxin Liu: Head of Immuno-Oncology Pipeline, GenNovo Biotech

 

11:10-11:25 Innovative TIL Therapy: Redefining the Treatment Landscape for Solid Tumors
Zhenjiu Wang: CMO, HUASAIBIO

 

11:25-11:40 The Ways to Enhance Efficacy and Avoid Risks in Preclinical Research of Anti-Tumor and Self Immune New Drugs
Jian Ge: Executive Vice President, Preclinical Research Division, Medicilon